Abridge
Vertical AI (legal, health, finance) · https://www.abridge.com
Verdict: Hold · Confidence: medium · Reviewed 2026-10-15
Abridge is a live clinical-documentation product in more than 150 U.S. health systems, with a $300 million Series E led by Andreessen Horowitz. TechCrunch, citing the Wall Street Journal, reported a $5.3 billion valuation and, citing The Information, $117 million of contracted ARR. Those revenue and valuation figures are secondary, and the workflow depends on Epic and other EHRs.
Rubric
| Dimension | Score (1–5) | Notes & sources |
|---|---|---|
| Real customers & revenue quality Are there named paying customers, recurring revenue, and retention evidence? | 4/5 | Abridge says it partners with more than 150 enterprise health systems, will support more than 50 million medical conversations this year, and retains over 90% of clinicians who start using it. TechCrunch reported $117 million of contracted ARR in Q1, attributed to The Information, which includes signed contracts not yet onboarded.
|
| Unit economics Do gross margins survive inference/compute costs? Is pricing durable? | Unknown | Unknown — no public figure found. |
| Moat Proprietary data, distribution, switching costs, or tech that is hard to copy? | 4/5 | Deployment across 55 specialties and 28 languages inside large health systems is hard to rip out. Abridge is extending from notes into coding and revenue-cycle capture at the point of care. Epic remains both a distribution channel and a competing surface.
|
| Platform risk Could a model provider or incumbent ship this as a feature? (higher score = lower risk) | 3/5 | TechCrunch describes Abridge's position as tied to early integration with Epic, and says the coding product competes with a feature from that same partner. Health-system switching costs are high, but the system of record is not Abridge's.
|
| Team & execution Shipping cadence, leadership track record, stability. | 4/5 | Cardiologist Shiv Rao is CEO. The company closed a $300 million Series E and says it has scaled from documentation into revenue-cycle workflows while reporting 60-70% burnout reduction and over 90% continued clinician use.
|
| Funding vs. traction Is capital raised justified by verifiable traction? | 3/5 | Company disclosure is a $300 million Series E. TechCrunch says that round was at $5.3 billion, after a $250 million February round at $2.75 billion, against $117 million of contracted ARR. The multiple is high and the ARR figure is contracted, not realized revenue.
|
| Hype signals Demo-driven marketing, vague metrics, valuation outrunning evidence? (higher score = fewer red flags) | 3/5 | Customer counts and retention are concrete. The valuation doubled in about four months on a secondary report, and burnout-reduction claims are company-stated without a linked study in the post.
|
Listing source: https://www.abridge.com. Revenue, users, and valuation figures appear only when publicly sourced; otherwise they are marked unknown.